Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study [PDF]
Frontiers in Microbiology, 2022 Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its ...
Yun Lu +13 more
doaj +2 more sources
Development of directly compressible ambroxol hydrochloride spherical crystals [PDF]
, 2018 One of the longest and most expensive parts of a standard tableting method is granulation. With the application of the direct compression tablet making, granulation can be omitted if the solid compound has proper compressibility and crystallographic ...
Gyulai Orsolya
core +3 more sources
Molecular Genetics and Metabolism Reports, 2020 Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the acid β-glucosidase encoding gene (GBA1), resulting in the deficient activity of acid β-glucosidase (GCase).
Giovanni Ciana +10 more
doaj +2 more sources
Biological and antimicrobial properties of the association Ambroxol and a water-soluble viscous liquid as a vehicle for a tricalcium silicate-based sealer [PDF]
Journal of Materials Science: Materials in Medicine, 2021 This study aimed to investigate the antimicrobial and biological properties of Ambroxol associated with glycerin (GLI), propylene glycol (PG), and polyethylene glycol (PEG) as a possible vehicle for an experimental tricalcium silicate sealer, with the ...
Índia Olinta de Azevedo Queiroz +8 more
doaj +2 more sources
Pharmaceutical Sciences and Research, 2023 Ambroxol HCl is a mucolytic agent often used to treat respiratory disorders associated with excess mucus secretion. This study aims to determine the beyond-use date (BUD) of ambroxol HCl syrup on the market based on analysis of the decrease in drug ...
Catur Jatmika +2 more
doaj +3 more sources
Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial [PDF]
BMC Infectious DiseasesBackground Ambroxol is a widely used mucoactive agent, but the efficacy of inhaled ambroxol in patients with lower respiratory tract infectious (LRTI) disease is poorly understood.
Di Wu +8 more
doaj +2 more sources
CNS Neuroscience and Therapeutics, 2008 For almost three decades ambroxol has been used in the therapy of airway diseases. In 2002, ambroxol lozenges were marketed for the treatment of sore throat making use of its local anesthetic effect. Detailed investigations of ambroxol with modern pharmacological methods yielded additional interesting results: ambroxol has been found to have profound ...
Thomas Weiser
exaly +3 more sources
Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease [PDF]
LifeBackground: Gaucher disease (GD) is a lysosomal storage disorder caused by deficiency of β-glucocerebrosidase, leading to accumulation of glucocerebroside in lysosomes.
Patryk Lipiński +11 more
doaj +2 more sources
Ambroxol attenuates detrimental effect of LPS-induced glia-mediated neuroinflammation, oxidative stress, and cognitive dysfunction in mice brain [PDF]
Frontiers in ImmunologyNeurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are multifactorial. Among various factors, lipopolysaccharides (LPSs) from Gram-negative bacteria, such as E.
Safi Ullah +10 more
doaj +2 more sources
Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation [PDF]
BMC MicrobiologyIt is critical to find novel therapeutic approaches owing to the dissemination of multidrug resistance (MDR) in pathogenic bacteria, particularly Staphylococcus aureus. FDA-drug repurposing is an important therapeutic tactic to fight MDR bacteria.
Ahmed A. Abdelaziz +4 more
doaj +2 more sources